The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Clinical Implications of Elevated Antiphospholipid Antibodies in Adult Patients with Primary Immune Thrombocytopenia

  • Yang, Young-Joon (Department of Internal Medicine, Daejeon Saint Mary’s Hospital, The Catholic University of Korea School of Medicine) ;
  • Yun, Gak-Won (Department of Internal Medicine, Chungnam National University School of Medicine) ;
  • Song, Ik-Chan (Department of Internal Medicine, Chungnam National University School of Medicine) ;
  • Baek, Seung-Woo (Department of Internal Medicine, Chungnam National University School of Medicine) ;
  • Lee, Kyu-Seop (Department of Internal Medicine, Chungnam National University School of Medicine) ;
  • Ryu, Hye-Won (Department of Internal Medicine, Chungnam National University School of Medicine) ;
  • Lee, Myung-Won (Department of Internal Medicine, Chungnam National University School of Medicine) ;
  • Lee, Hyo-Jin (Department of Internal Medicine, Chungnam National University School of Medicine) ;
  • Yun, Hwan-Jung (Department of Internal Medicine, Chungnam National University School of Medicine) ;
  • Kim, Sam-Yong (Department of Internal Medicine, Chungnam National University School of Medicine) ;
  • Jo, Deog-Yeon (Department of Internal Medicine, Chungnam National University School of Medicine)
  • Published : 2011.12.01
⟨ Previous Next ⟩

Abstract

Background/Aims: Antiphospholipid antibodies (aPL) have been detected in various proportions of patients with primary immune thrombocytopenia (ITP), but the clinical significance of this is debatable. The present study aimed to determine the frequency and clinical implications of elevated aPL in adult patients with ITP. Methods: We prospectively studied newly diagnosed adult patients with ITP who were enrolled between January 2003 and December 2008 at Chungnam National University Hospital. They were evaluated for the presence of lupus anticoagulant (LA) and anticardiolipin antibodies (aCL) at diagnosis and were followed for the development of thrombosis. Results: Seventy consecutive patients with ITP (median age, 48 years; range, 18 to 79) were enrolled. Twenty patients (28.5%) were positive for aPL at the time of diagnosis: aCL alone in 15 (75%), aCL and LA in two (10%), and LA alone in three (15%). Patients who had platelet counts < $50,000/{\mu}L$ were administered oral prednisolone with or without intravenous immune globulin. No difference was found between the aPL-positive and -negative groups regarding gender, initial platelet count, and response to the therapy. After a median follow-up of 20 months (range, 2 to 68), two of 20 patients who were aPL-positive (10%) developed thrombosis, whereas no thrombotic event was found among those who were aPL-negative. Conclusions: Our data suggest that aPL levels should be determined at the initial presentation of ITP and that patients found to be aPL-positive should receive closer follow-up for thrombotic events.

Keywords

References

  1. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115:168-186. https://doi.org/10.1182/blood-2009-06-225565
  2. Font J, Lopez-Soto A, Cervera R, et al. The 'primary' antiphospholipid syndrome: antiphospholipid antibody pattern and clinical features of a series of 23 patients. Autoimmunity 1991;9:69-75. https://doi.org/10.3109/08916939108997126
  3. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306. https://doi.org/10.1111/j.1538-7836.2006.01753.x
  4. Udayakumar N, Ezhilan N, Rajendiran C. Primary antiphospholipid antibody syndrome: how certain can you be of the diagnosis? J Clin Rheumatol 2007;13:53. https://doi.org/10.1097/01.rhu.0000255750.71659.64
  5. Ballerini G, Gemmati D, Moratelli S, Morelli P, Serino ML. Anticardiolipin antibody-related thrombocytopenia: persistent remission after splenectomy. Haematologica 1995;80:248-251.
  6. Diz-Kucukkaya R, Hacihanefioglu A, Yenerel M, et al. Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study. Blood 2001;98:1760-1764. https://doi.org/10.1182/blood.V98.6.1760
  7. Bidot CJ, Jy W, Horstman LL, Ahn ER, Yaniz M, Ahn YS. Antiphospholipid antibodies (APLA) in immune thrombocytopenic purpura (ITP) and antiphospholipid syndrome (APS). Am J Hematol 2006;81:391-396. https://doi.org/10.1002/ajh.20571
  8. Arfors L, Winiarski J, Lefvert AK. Prevalence of antibodies to cardiolipin in chronic ITP and reactivity with platelet membranes. Eur J Haematol 1996;56:230-234.
  9. Font J, Cervera R, Lopez-Soto A, et al. Anticardiolipin antibodies in patients with autoimmune diseases: isotype distribution and clinical associations. Clin Rheumatol 1989;8:475-483. https://doi.org/10.1007/BF02032099
  10. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937-951. https://doi.org/10.1182/blood-2009-03-209262
  11. Stasi R, Stipa E, Masi M, et al. Prevalence and clinical significance of elevated antiphospholipid antibodies in patients with idiopathic thrombocytopenic purpura. Blood 1994;84:4203-4208.
  12. Kaburaki J, Kuwana M, Ikeda Y. Anti-cardiolipin-beta2-GPI complex antibodies in idiopathic thrombocytopenic purpura. Intern Med 1998;37:796.
  13. Pierrot-Deseilligny Despujol C, Michel M, khellaf m, et al. Antiphospholipid antibodies in adults with immune thrombocytopenic purpura. Br J Haematol 2008;142:638-643. https://doi.org/10.1111/j.1365-2141.2008.07228.x
  14. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996;88:3-40.
  15. Page H. New criteria for diagnosing SLE. JAMA 1982;248:622. https://doi.org/10.1001/jama.1982.03330060004002
  16. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
  17. Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/ Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009;7:1737-1740. https://doi.org/10.1111/j.1538-7836.2009.03555.x
  18. Hughes GR. The anticardiolipin syndrome. Clin Exp Rheumatol 1985;3:285-286.

Cited by

  1. Association between the valine/leucine247 polymorphism of β2-glycoprotein I and susceptibility to anti-phospholipid syndrome: a meta-analysis vol.21, pp.8, 2011, https://doi.org/10.1177/0961203312440348
  2. The immunopathogenesis of immune thrombocytopenia: T cells still take center-stage vol.19, pp.5, 2011, https://doi.org/10.1097/moh.0b013e3283567541
  3. The Challenge of Bleeding in Antiphospholipid Antibody-Positive Patients vol.17, pp.2, 2011, https://doi.org/10.1007/s11926-014-0481-0
  4. Refractory Immunological Thrombocytopenia Purpura and Splenectomy in Pregnancy vol.2015, pp.None, 2015, https://doi.org/10.1155/2015/216362
  5. Current treatment of antiphospholipid syndrome: lights and shadows vol.11, pp.10, 2011, https://doi.org/10.1038/nrrheum.2015.88
  6. A Seeming Paradox : Ischemic Stroke in the Context of Idiopathic Thrombocytopenic Purpura vol.22, pp.2, 2016, https://doi.org/10.1177/1076029614545213
  7. Thromboembolism in patients with immune thrombocytopenia (ITP): a meta-analysis of observational studies vol.103, pp.6, 2011, https://doi.org/10.1007/s12185-016-1974-6
  8. IgG/IgM antiphospholipid antibodies present in the classification criteria for the antiphospholipid syndrome: a critical review of their association with thrombosis vol.14, pp.8, 2011, https://doi.org/10.1111/jth.13379
  9. Thromboembolism in adults with primary immune thrombocytopenia: a systematic literature review and meta‐analysis vol.97, pp.4, 2011, https://doi.org/10.1111/ejh.12777
  10. Incidence of Antiphospholipid Antibodies in Patients With Immune Thrombocytopenia and Correlation With Treatment With Steroids in North Indian Population vol.23, pp.6, 2011, https://doi.org/10.1177/1076029616643820
  11. Cardiovascular and bleeding outcomes in a population‐based cohort of patients with chronic immune thrombocytopenia vol.17, pp.6, 2011, https://doi.org/10.1111/jth.14446
  12. Multifocal avascular necrosis in a patient with refractory immune thrombocytopenia and antiphospholipid antibodies; case report and review of literature vol.30, pp.5, 2011, https://doi.org/10.1080/09537104.2018.1535701
  13. Potential therapeutics for antiphospholipid antibody associated thrombocytopenia: A systematic review and meta-analysis vol.30, pp.1, 2011, https://doi.org/10.1080/14397595.2018.1558934
  14. Update on diagnosis and treatment of immune thrombocytopenia vol.14, pp.5, 2021, https://doi.org/10.1080/17512433.2021.1903315